window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-113618785-7');

Partner news

Fraunhofer IPT hosts Lab Automation Day seminar, November 10th

Fraunhofer IPT logoOur partners at Fraunhofer Institute for Production Technology, IPT are hosting a Lab Automation Day on the morning of November 10th. Learn where can laboratory automation be profitably applied, which aspects have to be considered and how the implementation can be carried out successfully. This online training seminar is targeted to life science institutions, companies and research institutes. Here, presenters will demonstrate the advantages of lab automation as well as the considerations and approaches when implementing the technologies.

The seminar will be held online and in English, so it is open to everyone. Find the registration, costs and further information waiting for you here.

For further information, please contact Jelena Ochs M.Sc. by telephone +49 241 8904-571 or email

Read our interview with Jelena Ochs here.

Fraunhofer IPT hosts Lab Automation Day seminar, November 10th2020-09-16T12:01:10+00:00

PI Prof Bernd Giebel presents Web EV Talk acknowledging AutoCRAT

Prof. Dr Rer. Nat. Bernd Giebel, University Hospital Essen

AutoCRAT PI Prof. Dr Rer. Nat. Bernd Giebel of the Institute for Transfusion Medicine at the University Hospital Essen, Germany presented a talk entitled MSC-derived extracellular vesicles as part of the online Web EV talk series on July 16th, 2020. In his AutoCRAT-acknowledged talk, Bernd discusses how mesenchymal stem cell-derived extracellular vesicles are potential modulators of the immune system in many diseases. Watch the entire talk on YouTube.

The Web EV talk series is virtually hosted Dr Carolina Soekmadji and Prof. Jan Lötvall via Zoom each week. The programme aims to support networking and to push the science forward in the field of Extracellular Vesicles (EVs).

PI Prof Bernd Giebel presents Web EV Talk acknowledging AutoCRAT2020-08-18T10:39:23+00:00

Join Valitacell’s Bioprocessing Webinar Series starting August 19th

Our partners at Valitacell (https://www.valitacell.com/) are hosting a webinar, Automation and Imaging for Media Development in Cell Therapy Manufacturing on Wednesday, August 19th, 4 pm CEST/7 am PST. This is part of a Bioprocessing Webinar Series 2020 in partnership with TECAN. Customers from both companies will present their research and solutions for the development and production of biologicals.

Learn more about the speaker, Dr Marilina Piemontese, IRC Enterprise Postdoctoral Researcher, Regenerative Medicine Institute [REMEDI], NUI Galway, in Ireland and the content of this webinar here. You can register for this free webinar here.

Valitacell is an Irish biotechnology SME that develops, markets and sells technology to biopharmaceutical, contract development and manufacturing companies enabling them to make biological drugs faster, cheaper and with greater regulatory confidence. Within AutoCRAT, Valitacell works alongside consortium members to develop ChemStress® fingerprinting technology for MSC functional profiling throughout the cell manufacturing process and investigates the application of their Quantum technology in MSC secretome assessment. These analytical tools will be fully automated in collaboration with the Fraunhofer Institute of Production Technology.

Join Valitacell’s Bioprocessing Webinar Series starting August 19th2020-08-17T10:49:16+00:00

Prof Simonsson, U of Gothenburg invites abstracts and chairs iPSC symposium at TERMIS 2021

The much-anticipated 6th TERMIS meeting is slated for May 31- June 4th, 2021. The meeting will take place in Maastricht in the Netherlands. AutoCRAT PI Prof Stina Simonsson of the University of Gothenburg will chair the symposium: iPSC-based bioengineering for tissue regeneration during ageing and disease.  The deadline to submit abstracts is September 1st.

 

Prof Simonsson, U of Gothenburg invites abstracts and chairs iPSC symposium at TERMIS 20212020-07-30T11:57:55+00:00

Interview with Jelena Ochs, Fraunhofer Institute for Production Technology

Danielle Nicholson of Pintail Limited posed a few questions to Jelena Ochs of the Fraunhofer Institute for Production Technology (IPT) to gain her views on her work in automation research and development and AutoCRAT, in general.

Jelena Ochs

Jelena Ochs

Based in Aachen, Germany, The Fraunhofer Institute for Production Technology (https://www.ipt.fraunhofer.de/) is part of the Fraunhofer-Gesellschaft, Europe’s largest application-oriented research organisation. Within the business area “Life Sciences Engineering” their focus is on the research and development of pioneering technologies for the entire range of life sciences from the pharmaceutical industry and biotechnology to medical technology.

Please introduce yourself and tell us about your role within Fraunhofer IPT.

I am a technical biologist by training and I am with Fraunhofer IPT for more than four years now. I am also a research fellow in the automation in life sciences group and leading and coordinating project work on automation of bioprocesses.

Fraunhofer IPT is a leader in production technologies. Can you give us an overview of what the institute will provide in the context of AutoCRAT?

IPT has been working on laboratory automation for many years. This means exploring the question of how can we build robot-assisted laboratories that automate entire process chains, leaving minimal intervention necessary from the operator. We have been successfully applying this also for ATMP (Advanced therapy medicinal products) production (see AUTOSTEM, www.autostem2020.eu), where we produce mesenchymal stromal cells (MSC) in a robot-assisted, bioreactor-based process. For AutoCRAT, we will provide our existing infrastructure and expertise to:

    • extend automated processes towards the production of different cell and regenerative therapeutic products (induced pluripotent stem cells, or iPSC),
    • adding a quality control (QC) module for at-line process control and
    • enhancing the systems capabilities by making it even smarter and more functional (e.g. letting the robot clean the chamber instead of having a human operator to climb into the system).

In the end, we will have three modules (one for cell production, one for QC and one for extracellular vesicle (EV) purification) that are capable of producing a range of different cell types relevant for advanced therapies.

You have worked with several of the AutoCRAT partners in other projects, for example, AUTOSTEM. How is this an advantage?

We can build on what we have established – both physically and in terms of non-material achievements. For example, we will build on the AUTOSTEM pipeline to optimize and extend the system and exploit the findings from previous projects.

Also, interdisciplinary projects are a lot about communication. It takes certain effort for an interdisciplinary group to start speaking the same language, e.g. engineers have to understand requirements and specificities of cell culture, where living products are produced, while biologists and clinicians have to start thinking about standardization, automation and translation of processes that can be handled by robots and automated equipment. It is important that biologists and engineers work towards each other and not past each other.

IPT has been working in interdisciplinary teams for many years, but it is always an advantage to have a group where good communications and a joint understanding has been already established.

Interview with Jelena Ochs, Fraunhofer Institute for Production Technology2020-06-08T12:10:32+00:00

PARTNER NEWS: LUMC constructs the largest stem cell facility for the Netherlands and beyond

AutoCRAT partner Leiden University Medical Center (LUMC) will begin construction of the largest non-profit stem cell and gene therapy facility in the Netherlands in 2020. This will be one of the largest such facilities in Europe measuring at 4000 square metres. The Leiden facility is called NECSTGEN, the Netherlands Centre for the Clinical advancement of Stem Cell and Gene Therapies.

The NECSTGEN is a public-private partnership. Researchers and start-ups will soon be welcomed in Leiden, NL in order to accelerate the application of regenerative medicine therapies. NECSTGEN is in part a collaboration with the Canadian Centre for Commercialisation of Regenerative Medicine (CCRM), who realised a similar facility in Toronto.

Currently, there are limited affordable, non-profit facilities where cell and cell product development for regenerative medical treatments are manufactured at scale.

One of the founders of NECSTGEN, Gerard van Loon stated, “NECSTGEN is a 100% daughter of the LUMC and started particularly to boost the cell and gene therapy research in Leiden, and particularly the LUMC.”

Congratulations to LUMC and their partners for this great achievement and contribution to the regenerative medicine field!

Read the official press release here.

PARTNER NEWS: LUMC constructs the largest stem cell facility for the Netherlands and beyond2020-06-04T10:28:20+00:00
Go to Top